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Abstract 
Post-transplant lymphoproliferative disorders 
(PTLDs) are serious, life-threatening complications 
of transplantation, which represent a heterogeneous 
group of lymphoproliferative diseases and show a 
spectrum of clinical, morphologic, and molecular 
genetic features ranging from reactive polyclonal 
lesions to frank lymphomas. Monomorphic (M) 
PTLD fufill the criteria for one of the B-cell or T/NK 
cell neoplasms that are recognized in the 
immunocompetent host, which shows characteristic 
clinicopathological features and molecular 
involvement. 
KEYWORDS 
Post-transplant lymphoproliferative disorders; 
lymphoma; B-cell; T/NK cell 
Clinics and pathology 
Disease 
The term "post-transplant lymphoproliferative 
disorder" or disease (PTLD) was first introduced in 
1984 by Starzl ( Starzl et al.1984) .PTLDs are 
serious, life-threatening complications of solid-
organ transplantation (SOT) and bone marrow 
transplantation, and are associated with high 
mortality. PTLDs represent a heterogeneous group 
of lymphoproliferative diseases, which show a 
spectrum of clinical, morphologic, and molecular 
genetic features ranging from reactive polyclonal 
lesions to frank lymphomas. 
PTLDs are classified into early lesions, 
polymorphic, monomorphic and classical Hodgkin's 
lymphoma-like PTLD. 
M-PTLD shows characteristic clinicopathological 
features and molecular involvement. M- PTLD are 
composed of monotonous proliferation of 
transformed lymphoid cells or plasmacytic cells, 
there may be significant pleomorphism and 
variability of cell size within a given case. M-PTLD 
can be one of B-cell or T/NK-cell neoplasms, 
however, the small B-cell lymphoid neoplasms such 
asfollicular lymphomas or MALT lymphomas are 
not designated as PTLD. The M-PTLD should be 
dedignated as PTLD in the diagnostic line of the 
pathology report, and then further categorized based 
on the classification of lymphomas arising in the 
immunocompetent host ( Swerdlow, et al ,2008. 
Mucha, et al. 2010. His ED, et al , 2000). 
The B-cell M-PTLD are monoclonal transformed B 
lymphocytic or plasmacytic proliferations that fufill 
the criteria for a diffuse large B-cell lymphoma, less 
often a Burkitt lymphoma or a plasma cell neoplasm 
. The T/NK-cell type M-PTLD include PTLD that 
fufill the criteria for any of the T- or natural killer 
cell lymphomas. They include almost the entire 
spectrum of T- or NK-cell neoplasma, with the 
largest group being peripheral T-cell lymphoma, not 
otherwise specified type, followed by hepatosplenic 
T-cell lymphoma, extranodal NK/T-cell lymphoma, 
nasal type ( Swerdlow, et al , 2008). 
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Phenotype/cell stem origin 
The majority (>90%) of PTLD in solid organ 
recipients are of host origin and only a minority of 
donor origin. Donor origin PTLD appear to be most 
common in liver and lung allograft recipients, and 
frequently involve the allograft. In contrast, the 
majority of PTLD in bone marrow(BM) allograft 
recipients are of donor origin, as would be expected, 
since successful engraftment results in an immune 
system that is nearly exclusively of donor origin 
(Chadbum, et al ,1995. Swerdlow, et al ,2008). 
Phenotypically, in B-cell M- PTLD , the non-
plasmacytic lesions show B cell associated antigen 
(CD19, CD20, CD79a, PAX5), and most cases are 
of non-GC type based on immunohistochemistry. 
The EBV-positive cases usually have a late germinal 
center/post germinal center phenotype (CD10-
,BCL6+/-, IRF4/MUM1+), whereas the EBV 
negative cases as more likely to have a germinal 
center type phenotype (CD10+/-
,BCL6+,IRF4/MUM1-). In T/NK-cell type M-
PTLD, they show expression of pan-T-cell and 
sometimes NK-associated antigens. Depending on 
the specific type, they may express CD4 or CD8, 
CD30, ALK and either αβ or γδ T-cell receptors. 
About 1/3 of cases are EBV-positive (Swerdlow, et 
al ,2008). 
Epidemiology 
The incidence of PTLD ranges from 1-3 % in renal 
to 5-20 % in lung and intestinal transplantation, 
related to the type of transplanted organ, intensity of 
IS, age, and viral infection, etc.( Opelz, 2003. 
Opelz,1993.) In contrast, the incidence of PTLD 
after BMT is about 1.0 % for recipients from HLA-
compatible related donors (lower than that of SOT), 
but in up to 25 % for high-risk patients (Curtis, 
1999). However, the field has evolved during the last 
decade. Hoegh-Petersen et al. found a frequency of 
8.1 % among 307 allo-HSCT recipients who had also 
received ATG-based conditioning. Kamani et al. 
found an overall incidence of 2.3 % for post-
transplant malignancy (most of which were PTLD) 
in patients receiving such transplant for primary 
immunodeficiency disorders. The highest subgroup, 
those patients with Wiskott-Aldrich syndrome, had a 
3.3 % frequency. 
In our hospital, it is 1.5 % (9/585) from August 2002 
to October 2006 and about 1 % (9/857) from 
November 2006 to November 2009 after allo-HSCT, 
respectively. The incidence of PTLD was higher in 
mismatched or unrelated HSCT group than that of 
conventional one, 3.4 % (7/208), 2.3 % (1/44) versus 
0/323. It was also higher in patients with 
conditioning regimen including ATG than those 
without, 3.4 % (9/262) vs. 0/323. In North Ameica 
and Western Europe, the T/NK-cell type M-PTLD 
make up no more than 15% of PTLD (Swerdlow, et 
al ,2008. Chen, 2013) 
Clinics 
The clinical features of PTLD differ from those of 
lymphomas observed in the general population. 
Symptoms may be mild, such as fever, 
mononucleosis-like syndrome, lymphadenopathy, 
recurrent infections or severe organ dysfunction. The 
variable manifestation of PTLD depends on many 
factors, such as the type of transplanted organ or IS 
used, histopathology and time elapsed since 
transplantation. The first year after transplantation is 
important, in lung recipients, more than 50 % of all 
PTLDs develop during the first post-transplant year. 
Our data showed that 88.2 % of patients (15/17) were 
diagnosed within 7 months after transplantation (1.5-
7 months), and the median interval after 
transplantation to the diagnosis was 2.5 months 
(mean 4.7 months, range 1.5-19 months), shorter 
than that of SOT. The frequent sites of PTLD include 
GI (jejunum more often than colon), lymph nodes, 
and central nervous system, different from type to 
type of transplantation. 
The clinical presentation of patients with B-cell M-
PTLD is similar to that of the lymphomas or plasma 
cell neoplasms that they resemble, whereas the 
presentation of T/NK-cell M-PTLD depends on the 
type of neoplasm. Most cases present as extranodal 
sites, sometimes with associated lymphadenopathy 
(Opelz, et al, 2003. Swerdlow, et al ,2008. Johnson, 
et al, 2006. Swerdlow,2007). 
Pathology 
M-PTLD is characterized by effacement of the 
architecture. B-cell M-PTLD fulfill the conventional 
criteria for DLBCL, Burkitt lymphoma, 
plasmacytoma or myeloma. Some pleomorphic 
transformed cells and bizarre, multinecleated, RS-
like cells can be seen. The morphologic features of 
T/NK-cell M-PTLD are similar to the same T/NK-
cell lymphomas in immunocompetent hosts ( 
Knowles, et al, 1995.) 
Figure 1-4. Monomorphic B-cell PTLD. Diffuse 
large B cell lymphoma. 
Figure 5-12. Monomorphic T/NK-cell PTLD. 
Extranodal T/NK cell lymphoma, nasal type 
occurred in the intestinal tract of a heart transplant 
patient.
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Figure 1.  Effacement of the architecture and proliferative large lymphoid cells, with marked nucleoli. (HE 
stain) 
 
Figure 2.  The cells are positive for CD20. 
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Figure 3.  The proliferation index of Ki 67 is 95%. 
 
 
Figure 4.  Some cells are positive for EBER (in situ hridization). 
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Figure 5.  The intestinal wall is infiltrated by lymphoid tissue. 
 
 
Figure 6.  The neoplastic cells are monotonous and medium-sized, infiltrateing and destroying an artery. 
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Figure 7.  The cells are positive for CD3. 
 
 
Figure 8.   The cells are positive for CD56. 
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Figure 9.  The cells are positive for granzyme B. 
 
 
Figure 10.  The cells are positive for TIA1. 
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Figure 11.  The proliferation index of Ki 67 is 80%. 
 
 
Figure 12.  Some cells are positive for EBER. (in situ hridization). 
Treatment 
There is no consensus on the optimal treatment of 
PTLD. It is generally agreed that three major 
strategies should be applied: restoration of the 
recipient's immunity (to limit the EBV infection), 
elimination EBV and removal of neoplastic B cells. 
Reduction of IS or even withdrawal remains the first-
line treatment. With reduction of 
immunosuppression, virtually all early lesions 
regress and generally show good prognosis, whereas 
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half of P-PTLD regress and some will progress, the 
majority of M-PTLDs do not regress. DLI was 
effectively used in EBV-associated PTLD after 
mismatched/haploidentical haematopoietic stem cell 
transplantation (HSCT). Patients with lymph node 
localization have a relatively good outcome, and 
disseminated disease in contrast has a poor 
prognosis( Mucha, et al, 2010. Xu, et al, 2010). 
Prognosis 
The prognosis of PTLD is poor. The treatment of 
rejection episodes with OKT3 or ATG enhances the 
PTLD risk in patients who did not receive antibody 
induction, rejection therapy with OKT3 or ATG adds 
to the already increased lymphoma risk HLA 
matching is also a risk factor in the pathogenesis of 
PTLD, and HLA-B or HLA-DR mismatches 
especially seem to be critical. The number of HLA 
mismatches parallels with an increased risk of PTLD 
( Opelz, et al, 2003. Opelz, et al, 2010). 
Genetics 
Note 
In B-cell M-PTLD, clonal IG gene rearrangement is 
present in virtually all cases, and the majority 
contain EBV genomes, which, if present, are in 
clonal episomal form. Oncogene abnormalities 
(RAS or TP53 mutations and MYC rearrangements) 
may be found, and BCL6 gene somatic 
hypermutation is common, however, BCL6 
translocations are uncommon. Aberrant promoter 
hypermethylation and aberrant somatic 
hypermutation also occur in M-PTLD.  
 
In T/NK-cell M-PTLD, clonal T-cell receptor gene 
rearrangement and chromosomal abnormalities ( 
i(7)(q10) and +8) can be seen ( Swerdlow, et al 
,2008. Djokic M, et al, 2006.). 
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